LBPS

4D pharma plc [LBPS] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

LBPS Stock Summary

Earnings have grown 34.46% per last year.

EPS has been increasing for the past 3 years (Yearly statements)

Earnings are expected to fall -100% next year

In the News

LBPS Financial details

Company Rating

Market Cap

Income

Revenue

Book val./share

Cash/share

Dividend

Dividend %

Employees

106

Optionable

Shortable

Yes

Earnings

31 Mar 2022

P/E

-1.09

Forward P/E

PEG

P/S

P/B

1.08

P/C

P/FCF

Quick Ratio

3.17

Current Ratio

5.21

Debt / Equity

0.39

LT Debt / Equity

0.39

EPS (TTM)

EPS next Y

EPS next Q

EPS this Y

-17.03%

EPS next Y

EPS next 5Y

EPS last 5Y

Revenue last 5Y

Revenue Q/Q

EPS Q/Q

SMA20

SMA50

SMA100

Inst Own

Inst Trans

ROA

-54%

ROE

-106%

ROC

-0.71%

Gross Margin

Oper. Margin

-5190%

Profit Margin

-4448%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

1.61-1.65

52W High

52W Low

RSI

Rel Volume

Avg Volume

11.31K

Volume

Perf Week

Perf Month

Perf Quarter

Perf Half Y

Beta

3.26641

Volatility

0%, 0%

Prev Close

Price

Change

LBPS Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0	0	0.03	0.04	0.03
Net income per share	-2.51	-2.89	-2.94	-1.82	-1.51
Operating cash flow per share	-2.11	-2.8	-2.63	-1.59	-1.79
Free cash flow per share	-2.37	-2.87	-2.71	-1.61	-1.8
Cash per share	6.15	3.2	0.47	0.62	0.99
Book value per share	8.58	5.59	2.73	1.97	1.53
Tangible book value per share	6.77	3.83	1.02	0.98	0.63
Share holders equity per share	8.58	5.59	2.73	1.97	1.53
Interest debt per share	0.02	0.05	0.2	0.09	0.63
Market cap	87.62M	93.45M	89.8M	151.51M	115.49M
Enterprise value	75.79M	77.43M	87.08M	143.79M	107.32M
P/E ratio	-4.29	-3.94	-3.73	-5.84	-3.62
Price to sales ratio	0	0	425.61	283.72	160.85
POCF ratio	-5.1	-4.07	-4.17	-6.68	-3.05
PFCF ratio	-4.55	-3.98	-4.05	-6.63	-3.02
P/B Ratio	1.26	2.04	4.02	5.42	3.56
PTB ratio	1.26	2.04	4.02	5.42	3.56
EV to sales	0	0	412.7	269.27	149.47
Enterprise value over EBITDA	-3.31	-2.88	-3.15	-4.96	-3.57
EV to operating cash flow	-4.41	-3.38	-4.04	-6.34	-2.83
EV to free cash flow	-3.93	-3.3	-3.93	-6.29	-2.81
Earnings yield	-0.23	-0.25	-0.27	-0.17	-0.28
Free cash flow yield	-0.22	-0.25	-0.25	-0.15	-0.33
Debt to equity	0	0	0.05	0.04	0.39
Debt to assets	0	0	0.04	0.03	0.22
Net debt to EBITDA	0.52	0.6	0.1	0.27	0.27
Current ratio	11.6	6.4	1.8	2.59	5.21
Interest coverage	-267.48	-103.45	-80.69	-237.73	-54.01
Income quality	0.84	0.97	0.9	0.87	1.19
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	7.45	7.67	22.13
Research and developement to revenue	0	0	125.65	41.28	30.13
Intangibles to total assets	0.19	0.27	0.46	0.4	0.33
Capex to operating cash flow	0.12	0.02	0.03	0.01	0.01
Capex to revenue	0	0	-2.82	-0.33	-0.39
Capex to depreciation	-2.12	-0.45	-0.46	-0.15	-0.21
Stock based compensation to revenue	0	0	1.27	6.24	0.99
Graham number	22.02	19.08	13.44	8.98	7.2
ROIC	-0.4	-0.65	-1.38	-1.17	-0.68
Return on tangible assets	-0.32	-0.62	-1.45	-1.21	-0.81
Graham Net	5.18	2.39	-0.53	0.1	-0.25
Working capital	52.82M	27.98M	5.01M	10.27M	27.88M
Tangible asset value	55.11M	31.32M	8.36M	13.95M	13.27M
Net current asset value	49.85M	26.32M	3.01M	9.27M	8.12M
Invested capital	0	0	0.05	0.04	0.39
Average receivables	0	0	0	0	0.5
Average payables	1.48M	1.87M	1.58M	2.26M	2.49M
Average inventory	245.5K	271.5K	244K	244.5K	329.05K
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	718K
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-0.29	-0.52	-1.08	-0.93	-0.99
Capex per share	-0.26	-0.07	-0.07	-0.01	-0.01

Quarterly Fundamentals Overview

Last date of statement is 2021-12-31 for Q4

Metric	2019-06-30	2020-06-30	2020-12-31	2021-06-30	2021-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0	0.01	0	0	0
Net income per share	0	-0.3	0	0	0
Operating cash flow per share	0	0	0	0	0
Free cash flow per share	0	0	0	0	0
Cash per share	0	0.43	0	0	0
Book value per share	0	1.35	0	0	0
Tangible book value per share	0	1.35	0	0	0
Share holders equity per share	0	1.35	0	0	0
Interest debt per share	0	0.05	0	0	0
Market cap	0	271.18M	0	0	0
Enterprise value	-11.8M	262.26M	-7.72M	-19.74M	-8.17M
P/E ratio	0	-9.88	0	0	0
Price to sales ratio	0	1.97K	0	0	0
POCF ratio	0	0	0	0	0
PFCF ratio	0	-3.39K	0	0	0
P/B Ratio	0	8.62	0	0	0
PTB ratio	0	8.62	0	0	0
EV to sales	0	1.91K	0	0	0
Enterprise value over EBITDA	0	-34.6	0	0	0
EV to operating cash flow	0	0	0	0	0
EV to free cash flow	0	-3.28K	0	0	0
Earnings yield	0	-0.03	0	0	0
Free cash flow yield	0	0	0	0	0
Debt to equity	0.03	0.03	0.04	0.03	0.39
Debt to assets	0.03	0.03	0.03	0.02	0.22
Net debt to EBITDA	0	1.18	0	0	0
Current ratio	6.62	3.16	2.59	4.22	5.21
Interest coverage	0	187.8	0	0	0
Income quality	0	0	0	0	0
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	16.01	0	0	0
Research and developement to revenue	0	45.16	0	0	0
Intangibles to total assets	0	0	0.4	0	0.33
Capex to operating cash flow	0	0	0	0	0
Capex to revenue	0	-0.58	0	0	0
Capex to depreciation	0	-0.26	0	0	0
Stock based compensation to revenue	0	0	0	0	0
Graham number	0	3	0	0	0
ROIC	0	-0.21	0	0	0
Return on tangible assets	0	-0.17	0	0	0
Graham Net	0	0.07	0	0	0
Working capital	18.99M	14.02M	10.27M	22.67M	27.88M
Tangible asset value	34.97M	31.46M	13.95M	39.66M	13.27M
Net current asset value	14.78M	12.02M	9.27M	21.72M	8.12M
Invested capital	0.03	0.03	0.04	0.03	0.39
Average receivables	0	0	0	0	0
Average payables	0	0	4.86M	5.13M	4.32M
Average inventory	0	0	251.5K	298K	152.5K
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	0	-0.22	0	0	0
Capex per share	0	0	0	0	0

LBPS Frequently Asked Questions

What is 4D pharma plc stock symbol ?

4D pharma plc is a GB stock and trading under the symbol LBPS

What is 4D pharma plc stock quote today ?

4D pharma plc stock price is $- today.

Is 4D pharma plc stock public?

Yes, 4D pharma plc is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Check Those

Similar Market Cap

Company Profile

Volume Average 11.31K
Employee 106
CEO Mr. Duncan Joseph Peyton
Headquarters Leeds,GB
IPO Date 2021-03-22
Website https://www.4dpharmaplc.com

4D pharma plc, together with its subsidiaries, develops live biotherapeutic products (LBPs) in the United Kingdom. The company develops therapeutic candidates, including MRx0518 for the treatment of cancer and immune-oncology diseases; MRx-4DP0004 for the treatment of asthma; MRx0029 and MRx0005 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, such as MRx1299 for solid tumors, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. In addition, the company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate MRx0518; strategic collaboration agreement with University of Texas MD Anderson for discovery and development of LBPs in oncology; and Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda, MRx0518 in patients with solid tumors, and to discover and develop LBPs for vaccines. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.